Meet Our Experts

Finding a doctor can be simple and easy. Search for a physician by name or specialty.

Modify Search

Andrea Vambutas, MD, FACS

Andrea Vambutas, MD, FACS

The Center for Hearing & Balance Disorders

Clinical Offices

Apelian Cochlear Implant Center
430 Lakeville Rd.
New Hyde Park, NY 11040
Tel: (718) 470-7550
Fax: (718) 470-4281

Academic Appointments

  • Chief of Division - Research Otolaryngology, Long Island Jewish Medical Center
  • Chief of Division - Otology/Neurotology, Long Island Jewish Medical Center
  • Director, Center for Hearing & Balance Disorders, New York Head & Neck Institute
  • Director, Basic & Clinical Research, New York Head & Neck Institute
  • Medical Director, Apelian Cochlear Implant Center
  • Professor of Otolaryngology & Molecular Medicine, Hofstra North Shore-LIJ School of Medicine
  • Investigator, Center for Autoimmune & Musculoskeletal Disorders, Feinstein Institute for Medical Research

About Andrea Vambutas MD, FACS

Dr. Andrea Vambutas is the Director for the Center of Hearing & Balance at the New York Head & Neck Institute. She is also the Medical Director of the Apelian Cochlear Implant Program and Professor of Otolaryngology & Molecular Medicine. She was instrumental in developing the Apelian Cochlear Implant Center, which celebrated its 10th anniversary in 2011. The center cares for infants and adults. The cochlear implant team is comprised of surgeons, audiologists, speech pathologists, social workers, sign language interpreters and deaf educators who provide all aspects of evaluation prior to, and rehabilitation following cochlear implantation. The center has been the recipient of many complicated otologic cases, and difficult clinical problems.

Dr. Vambutas is a clinician-scientist that studies immune responses and their effect on hearing. There are three unique forms of hearing loss that may be amenable to medical therapy for recovery of natural hearing: Autoimmune Inner Ear Disease, Sudden Sensorineural Hearing Loss and Meniere’s Disease. Timely treatment with steroids results in hearing recovery in about 60% of cases. Unfortunately, that response is lost over time with repetitive treatment. For those that fail to respond to corticosteroids, there are no alternate treatments. Deteriorating hearing is rehabilitated with hearing aids or cochlear implants. Despite how beneficial these devices are, they do not select for what we want to hear, unlike our brains that do it naturally and seamlessly.

Her research interests are in the restoration of natural hearing in these steroid resistant patients. To this end, her laboratory has identified the critical role of an inflammatory protein, interleukin-1 (IL-1), in this disease. Her research group is running a NIH-sponsored phase I open-label clinical trial to determine if blockade of IL-1 can prevent further hearing loss in these steroid-resistant individuals ( NCT01267994). Her laboratory is also trying to better understand the molecular mechanisms behind these diseases, specifically in distinguishing steroid sensitive and resistant hearing loss which would identify new biologic markers of disease.

Comprehensive Otology Expertise:

  • Cochlear Implants
  • Chronic Ear Surgery/Cholesteatoma
  • Stapedectomy
  • BAHA
  • Tympanoplasty
  • Autoimmune Inner Ear Disease
  • Meniere’s Disease
  • Sudden Sensorineural Hearing Loss


  • MD – Albert Einstein College of Medicine


  • Otolaryngology – Long Island Jewish Medical Center
  • General Surgery – Long Island Jewish Medical Center


  • Neurotology – Minnesota Ear Head & Neck Clinic

Board Certification:

  • Otolaryngology – American Board of Otolaryngology

Awards and Recognition:

  • Castle Connolley, Best Doctors
  • Best Doctors in America
  • Outstanding Teacher Awards, North Shore-LIJ Health
  • System & Montefiore Medical Center
  • Service Award, American Academy of Otolaryngology HNS

Relevant Recent Publications:

  • Vambutas, A., DeVoti, J., Goldofsky, E., Gordon, M., Lesser, M., Bonagura, V. Alternate splicing of Interleukin-1 Receptor Type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. PLoS ONE, (4):e5293. Epub 2009 Apr 29
  • Spivak, L., Auerbach, C., Vambutas, A., Geshkovich, S., Wexler, L., Popecki, B. Electrical Compound Action Potentials Recorded with Automated Neural Response Telemetry: Threshold Changes as a Function of Time and Electrode Position. Ear Hear. 2011 Feb;32(1):104-13.
  • Pathak, S., Goldofsky, E., Vivas, E., Bonagura, V., Vambutas, A. Interleukin-1ß is over-expressed and aberrantly regulated in corticosteroid non-responders with Autoimmune Inner Ear Disease. J Immunol. 2011 Feb 1;186(3):1870-9. Epub 2011 Jan 3.
  • Svrakic, M, Pathak, S, Goldofsky, E, Hoffman, R, Chandrasekhar, S, Sperling, N, Alexiades, G, Ashbach, M, Vambutas, A. Diagnostic and prognostic utility of measuring TNF-a in the peripheral circulation of patients with immune-mediated sensorineural hearing loss. Accepted, Archives of Otolaryngology 2012

Professional Affiliations:

  • Diplomat: American Academy of Otolaryngology-Head and Neck Surgery
  • Fellow: American College of Surgeons
  • Fellow, American Neurotology Society
  • Elected Member: New York Otologic Society
  • Elected Member: Henry Kunkel Society
  • Elected Member: American Association of Immunologists

Clinical Trials and Research Interests:

  • Principal Investigator: A phase I clinical trial of Anakinra for Steroid-Resistant AIED patients, Funding Source: NIDCD, NIH R21/R33 DC011827 NCT01267994
    A clinical trial for steroid-resistant patients using a drug that blocks IL-1ß
  • Principal Investigator: A decoy receptor as a novel biomarker for Autoimmune Inner Ear Disease Funding Source: NIDCD, NIH R21 DC008894
    An IRB approved study to try to identify novel biomarkers and genetic risk factors for development of immune mediated hearing loss, and inflammatory factors that may predict steroid responsiveness and hearing recovery
  • Site Investigator: Protocol OTO-104-201101: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study of OTO-104 Versus Placebo given as a Single Intratympanic Injection in Subjects with Meniere’s Disease
    Sponsor: Otonomy, Inc.
    A clinical trial for a new therapy in Meniere’s Disease

Contact Image
Talk to Someone
In Manhattan:
    (212) 434-4500
In Long Island:
    (718) 470-7550
    (516) 470-7550
In Staten Island:
    (718) 226-6110
Help save lives!
Make a Donation